Connect with us

Hi, what are you looking for?

Editor's Pick

Trump FDA pick clears last hurdle after flipping vaccine question on Dem in confirmation hearing

President Donald Trump’s choice to lead the Food and Drug Administration (FDA), Johns Hopkins School of Medicine professor Dr. Marty Makary, cleared a key vote in the Senate on Tuesday, the last such test before his final confirmation vote.

The Senate voted 56-44 to invoke cloture on the nomination.

A final vote to confirm the FDA nominee is slated for after 8 p.m. Tuesday.

Makary, a former Fox News medical contributor, went before the Senate Committee on Health, Education, Labor and Pensions (HELP) earlier this month and answered various questions on vaccines, chronic illness, food safety and abortion.

During his hearing, the nominee faced scrutiny over an FDA vaccine meeting that was reportedly postponed at the last minute.

‘So if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Makary at the time.

He responded that he ‘would reevaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening.’

When this response wasn’t good enough for Murray, Makary flipped the question, telling her to confront the Biden administration. ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster,’ he said.

He was referring to the Biden administration in 2021 pushing through FDA approval for a COVID-19 booster for everyone over the age of 18.

‘The FDA did not hold a meeting of the Vaccines and Related Biological Products Advisory Committee on these actions,’ read a press release at the time, ‘as the agency previously convened the committee for extensive discussions regarding the use of booster doses of COVID-19 vaccines and, after review of both Pfizer’s and Moderna’s EUA requests, the FDA concluded that the requests do not raise questions that would benefit from additional discussion by committee members.’

Committee member Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, criticized the administration’s move, saying, ‘We’re being asked to approve this as a three-dose vaccine for people 16 years of age and older, without any clear evidence if the third dose for a younger person when compared to an elderly person is of value.’

Makary has long been a critic of the administration he is poised to lead. He wrote an opinion piece in 2021, calling for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

‘We now have a generational opportunity in American healthcare,’ he said at his hearing. ‘President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health.’

This post appeared first on FOX NEWS

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    You May Also Like

    Investing

    Newmont (NYSE: NEM) reported mixed financial results even as the price of gold approached its all-time high. In all, the company’s earnings per share...

    Investing

    Fisker (NYSE: FSR) stock price has been one of the best-performing electric vehicle (EV) stocks this week even as Tesla slumped. The shares jumped...

    Investing

    The Fox Corporation (NASDAQ: FOX) stock price has been under pressure as investors come to terms with the abrupt firing of Tucker Carlson. The...

    Investing

    NatWest (LON: NWG) share price rose sharply, helped by the strong results from Barclays. The stock jumped to a high of 274.8p, which was...




    Disclaimer: Oldamericanbroker.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the-company.


    Copyright © 2025 Oldamericanbroker.com